• Home
  • Commercial & Medical
  • PepGen’s muscle disease program posts poor mid-stage results as one patient’s data get markedly worse

A new cut of Phase 2 data on PepGen’s beleaguered oligonucleotide therapy for a genetic nerve and muscle disease has shown disappointing efficacy compared with analysts’ expectations.

The therapy, known as PGN-EDODM1, is intended to …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844